Stay updated with breaking news from Bcrx. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX – Get Free Report) was the target of unusually large options trading on Monday. Stock investors acquired 2,478 call options on the stock. This is an increase of approximately 59% compared to the average volume of 1,554 call options. Analyst Ratings Changes Separately, Needham & Company LLC reiterated a “buy” rating […] ....
MA Private Wealth purchased a new position in shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX – Free Report) during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund purchased 12,700 shares of the biotechnology company’s stock, valued at approximately $76,000. Several other institutional investors also […] ....
Shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX – Get Free Report) have been given an average recommendation of “Buy” by the seven brokerages that are presently covering the company, Marketbeat.com reports. Seven equities research analysts have rated the stock with a buy rating. The average 12-month price target among analysts that have covered the stock in […] ....
E Fund Management Co. Ltd. trimmed its holdings in shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX – Free Report) by 20.8% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 41,497 shares of the biotechnology company’s stock after selling 10,926 shares […] ....
Jump Financial LLC grew its position in shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX – Free Report) by 371.5% in the third quarter, according to its most recent filing with the SEC. The fund owned 404,913 shares of the biotechnology company’s stock after acquiring an additional 319,037 shares during the quarter. Jump Financial LLC’s holdings in […] ....